

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Icosapent ethyl for reducing the risk of cardiovascular events due to hypertriglyceridemia ID3831

Provisional stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • <u>A</u>marin Coporation (Icosapent ethyl) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Arrythmia Alliance • Atrial Fibrillation Association • Blood Pressure UK • British Cardiac Patients Association • Cardiac Risk in the Young • Cardiomyopathy UK • Cardiovascular Care Partnership • Circulation Foundation • Coronary Prevention Group • Different Strokes • Genetic Alliance • HEART UK • Network of Sikh Organisations • Pumping Marvellous Foundation • Somerville Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association • Stroke Information • Thrombosis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Genetic Nurses and Counsellors • British Association for Nursing in Cardiovascular Care • British Association of Stroke Physicians • British Atherosclerosis Society • British Cardiovascular Intervention Society • British Cardiovascular Society 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (atorvastatin, rosuvastatin, simvastatin) • Actavis UK (pravastatin) • Almus (pravastatin, simvastatin) • Aristo Pharma (rosuvastatin) • Aspire Pharma (fluvastatin) • AstraZeneca (rosuvastatin) • Bristol Laboratories (atorvastatin, simvastatin) • Brown & Burk (simvastatin) • Consilient Health (atorvastatin, rosuvastatin) • Crescent Pharma (simvastatin)

Provisional stakeholder list for the technology appraisal of icosapent ethyl for reducing the risk of cardiovascular events due to hypertriglyceridemia ID3831

Issue date: September 2020

<ul style="list-style-type: none"> • British Geriatrics Society • British Heart Foundation • British Heart Rhythm Society • British Nuclear Cardiology Society • British Society for Gene and Cell Therapy • British Society for Genetic Medicine • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Society for Heart Failure • British Society for Human Genetics • British Society of Cardiovascular Imaging • British Society for Cardiovascular Research • Clinical Leaders of Thrombosis • National Heart and Lung Institute • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science and Technology • Society for Vascular Nurses • Society for Vascular Technology • UK Clinical Pharmacy Association • UK Genetic Testing Network • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department for Health and Social Care • NHS England • NHS Nottingham City CCG • NHS Southwark CCG • Welsh Government 	<ul style="list-style-type: none"> • Dexcel Pharma (atorvastatin, simvastatin) • FlamingoPharma UK (atorvastatin) • Genesis Pharmaceuticals (simvastatin) • Macleods Pharma UK) (rosuvastatin) • Medreich (pravastatin, rosuvastatin, simvastatin) • Merck Sharp & Dohme (simvastatin) • Milpharm (pravastatin, rosuvastatin, simvastatin) • Mylan (atorvastatin, pravastatin, rosuvastatin) • Novartis (fluvastatin) • Ranbaxy (atorvastatin) • Relonchem (simvastatin) • Sandoz (fluvastatin, rosuvastatin, simvastatin) • Sigma Pharmaceuticals (atorvastatin, pravastatin, simvastatin) • Sun Pharmaceuticals (rosuvastatin) • Torrent Pharmaceuticals (fluvastatin) • Wockhardt UK (atorvastatin) • Xiromed (atorvastatin, rosuvastatin) • Zentiva (atorvastatin, rosuvastatin, simvastatin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cardiac and Cardiology Research Dept, Barts • Cochrane Heart Group • Cochrane Stroke Group • Cochrane Vascular • European Council for Cardiovascular Research • MRC Clinical Trials Unit • National Centre for Cardiovascular Prevention and Outcomes • Heart Research UK • National Institute for Health Research • Society for Research in Rehabilitation • Wellcome Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
---	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.)

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.